FBRX NASDAQ Week ended 28 Aug 2026

Weekly Investor Report

Forte Biosciences Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 76.99 USD
0.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 112.5% above the Trend Line and sits at 99.7% of its 52-week range. The latest completed week returned 0.1%, after a 0.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bearish with 28/100 conviction, while the latest news-sentiment score is 50/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal.

Setup score 56 out of 100
Latest Close 76.99 USD 28 Aug 2026
1W Return 0.1% latest completed week
4W Return 0.5% short-term follow-through
12W Return 366.0% quarterly tape
Trend Breadth 82.7% 43 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • The trend backdrop is active with a 6-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 12 reversal markers appear in the recent smart-money tape.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.1% Latest completed week; four-week move 0.5%. Indicator stack 66/75 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bearish 28/100 conviction; expected move 2.8%. News sentiment 50/100 4 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 112.5% above the Trend Line and sits at 99.7% of its 52-week range. The latest completed week returned 0.1%, after a 0.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug 14 Aug 21 Aug 28 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6912-week average 0.45

12-week confirmation

Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership8/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.69Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1212 reversal markers

No recent accumulation markers. 12 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 0.5% over four weeks, 366.0% over 12 weeks, and 599.9% over one year. The current trend has remained active for 6 consecutive weeks.

Performance by holding period

1W0.1%
4W0.5%
12W366.0%
26W154.8%
52W599.9%
Active trend streak6 weeks
Active weeks in one year43
Trend breadth82.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.37Latest activity-pressure read.
Pressure change-0.7%Four-week change in activity pressure.
Leadership142.65Latest relative-leadership reading.
RS change-27.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 18 Sep 2026 Financial statements through 30 Jun 2026 Field coverage 61% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength62/100Blend of value, momentum, and quality. Underlying universe rank 39; rank 1 is best.
Value56/100Relative valuation strength. Underlying universe rank 45; rank 1 is best.
Quality53/100Profitability and accounting quality. Underlying universe rank 48; rank 1 is best.
Momentum55/100Medium-term price momentum. Underlying universe rank 46; rank 1 is best.
Growth55/100Revenue and earnings growth. Underlying universe rank 46; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-4.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-1.4%
Net share repurchases relative to market value.
Shareholder yield
-1.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

FBRX shows bearish options pressure with a 28/100 conviction score, put-call volume ratio of 3.55, expected move of 2.8%, and Sharemaestro trend signal active.

Conviction28/100
Expected move2.8%
Put/call volume3.55
Pressure-54
Speculation18
Volatility16
Trend agreement0
Open options detail
Insider activity0 / 20

0 acquisitions and 20 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment50/100

Weighted news tone is neutral across 4 relevant articles.

0 positive · 4 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move2.8%Nearest-chain priced movement where available.
52-week drawdown-0.3%Distance below the 52-week high.
13-week volatility30.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+109.9%Week of 10 Jul.
Worst week-19.1%Week of 24 Apr.
Latest week+0.1%Week of 28 Aug.

Shape of recent returns

Strong gains8
Modest gains7
Flat weeks0
Modest losses3
Sharp losses8
Recent vol30.2%13-week weekly-return volatility.
Base vol20.6%52-week weekly-return volatility.
Up/down split31/21Count of positive and negative weeks in the 52-week window.
Average skew14.9% / -8.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape53/100

Trend, activity pressure, participation, and risk combine to a 53/100 tape read.

 Indicator analysis50/100

Latest 12-week confirmation: trend 6/12, activity pressure 7/12, relative leadership 8/12.

Activity pressure 0.69; 12 reversal markers Factors56/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 85; Small Cap Core rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options36/100

FBRX shows bearish options pressure with a 28/100 conviction score, put-call volume ratio of 3.55, expected move of 2.8%, and Sharemaestro trend signal active.

Bearish · Put-side pressure · Expected move 2.8% Sentiment50/100

Weighted news tone is neutral across 4 relevant articles.

Forte Biosciences stock trades on Nasdaq as clinical data shape valuation Insiders0 / 20

0 acquisitions and 20 disposals in the latest 180-day insider tape.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
28 Aug 202676.99 USD0.1%36.24 USD18.46 USD1.37142.653.9MOn
21 Aug 202676.92 USD0.1%34.64 USD18.09 USD1.50153.1313.0MOn
14 Aug 202676.83 USD0.1%33.14 USD17.74 USD1.47156.925.4MOn
7 Aug 202676.79 USD0.2%31.70 USD17.38 USD1.45170.446.0MOn
31 Jul 202676.60 USD39.8%29.93 USD17.03 USD1.38196.3530.5MOn
24 Jul 202654.78 USD12.1%28.17 USD16.68 USD0.75123.863.4MOn
17 Jul 202648.86 USD11.2%27.27 USD16.49 USD0.30102.973.4MOff
10 Jul 202643.92 USD109.9%26.63 USD16.33 USD-0.3980.079.3MOff
3 Jul 202620.92 USD-0.5%25.88 USD16.21 USD-1.07-10.561.6MOff
26 Jun 202621.03 USD17.8%25.84 USD16.24 USD-1.25-9.064.1MOff
19 Jun 202617.85 USD1.7%25.76 USD16.27 USD-1.59-25.97696.1KOff
12 Jun 202617.56 USD6.3%25.78 USD16.32 USD-1.58-25.391.3MOff
5 Jun 202616.52 USD-13.4%25.67 USD16.37 USD-1.48-28.131.8MOff
29 May 202619.07 USD-11.7%25.52 USD16.42 USD-1.37-20.68869.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context